170 likes | 362 Views
Goals of this Session. Review concepts of shared decision making.Describe results of fous groups to assess consumers' perceptions of sources of medical information.Describe our work developing tools to promote shared decision making.. The Role of Evidence in Shared Decision Making. What is eviden
E N D
1. Promoting Patient Involvement in Medication Decisions David H. Hickam, MD, MPH
Professor, Dept. of Medicine
Oregon Health & Science University
Portland, Oregon
2. Goals of this Session Review concepts of shared decision making.
Describe results of fous groups to assess consumers perceptions of sources of medical information.
Describe our work developing tools to promote shared decision making.
3. The Role of Evidence in Shared Decision Making What is evidence?
How does evidence inform medical decisions?
Can clinicians and patients communicate about evidence?
Are simple evidence-based decision tools useful?
4. Clinical Problems for which Decision Aids are Useful
5. Options for Tools to Promote Shared Decision Making simple: (provide probabilities, summary preferences in literature or by other patients or list of advantages disadvantages, coached steps toward decision).
Or complex: all of above plus one or more of the following: customized risk tools, probabilities that adjust with risk level, explicit values clarification, etc.
simple: (provide probabilities, summary preferences in literature or by other patients or list of advantages disadvantages, coached steps toward decision).
Or complex: all of above plus one or more of the following: customized risk tools, probabilities that adjust with risk level, explicit values clarification, etc.
simple: (provide probabilities, summary preferences in literature or by other patients or list of advantages disadvantages, coached steps toward decision).
6. Focus Groups to Assess Consumers Perceptions of Information Sources Perceived need for information about conditions and treatments.
Perceptions about sharing decisions with clinicians.
Where the participants obtain information.
Brief review of examples.
7. Focus Group Participants 18 focus groups (total of 113 participants)
Membership in each group defined by a particular chronic disease
Arthritis
Hypertension
Type 2 diabetes
Osteoporosis
8. Focus Group Characteristics Two-thirds female
60% age 60 or greater
75% Caucasian
43% college graduates
44% had used Internet in last month.
One-third rated their health as fair or poor.
9. Preferences for Information Sources Short and easy to read.
Many participants were not comfortable with Internet as information source.
Desire for positive information: often an issue when evidence is negative.
Framing of mortality information.
Trusted sources of information such as government and, AARP, or the Arthritis Foundation
Distrust in industry
10. Preferences for Content of Information Sources Consensus that information about benefits is the most important.
Participants understand benefit/harm trade-offs.
Desire that side effect information be thorough.
Comparison to non-medical treatments.
11. Perspective about Interactions with Providers Consensus on value of shared decision making.
Few participants reported collaborative, trusting relationships with clinicians.
Clinic visits tend to be rushed.
Some felt pressure to make hurried decisions.
Skepticism about recommendations to talk to your doctor.
Endorsement of tools that provide new information.
12. Principles for the Use of Evidence in Decision Tools Include evidence about both benefits and harms of the alternatives.
Indicate where the evidence in inconclusive.
Make the information actionable.
Need clarity about what the decisions are and how to approach those decisions.
13. Key Features of Eisenberg Center Summary Guides Brief & focused on key messages
Explicitly designed for audiences
Style template
Benefits, Risks, Trade-offs
Plain language
Appropriate literacy & numeracy levels
Actionable information
14. Up Front Bottom Line
15. Understanding the Benefits
16. Decision Coaching
17. Actionable Numeric Data For treatments of early stage prostate cancer:
Proportion of men reporting impotence following each treatment, at 2 years:
58% after radical prostatectomy
43% after radiation therapy
86% with hormonal therapy
33% with watchful waiting
18. Conclusions about Evidence Translation Both clinicians and consumers are interested in evidence and believe that it influences decisions.
Credibility is crucial.
We do not know very much about how clinicians and patients communicate about evidence.
Consumers perceive that evidence-based decision tools might be useful.